Literature DB >> 12966029

Mutations in the human LARGE gene cause MDC1D, a novel form of congenital muscular dystrophy with severe mental retardation and abnormal glycosylation of alpha-dystroglycan.

Cheryl Longman1, Martin Brockington, Silvia Torelli, Cecilia Jimenez-Mallebrera, Colin Kennedy, Nofal Khalil, Lucy Feng, Ravindra K Saran, Thomas Voit, Luciano Merlini, Caroline A Sewry, Susan C Brown, Francesco Muntoni.   

Abstract

The congenital muscular dystrophies (CMD) are a heterogeneous group of autosomal recessive disorders. A new pathomechanism has recently been identified in a group of these disorders in which known or putative glycosyltransferases are defective. Common to all these conditions is the hypoglycosylation of alpha-dystroglycan. Fukuyama CMD, muscle-eye-brain disease and Walker-Warburg syndrome, each associated with eye abnormalities and neuronal migration defects, result from mutations in fukutin, POMGnT1 and POMT1, respectively, while mutations in the fukutin-related protein (FKRP) gene cause congenital muscular dystrophy 1C, typically lacking brain involvement. Another putative glycosyltransferase, Large, is mutated in the myodystrophy mouse. The human homologue of this gene is therefore a strong candidate for involvement in novel forms of muscular dystrophy. We studied 36 patients with muscular dystrophy and either mental retardation, structural brain changes or abnormal alpha-dystroglycan immunolabelling, unlinked to any reported CMD loci. Linkage analysis in seven informative families excluded involvement of LARGE but sequencing of this gene in the remaining 29 families identified one patient with a G1525A (Glu509Lys) missense mutation and a 1 bp insertion, 1999insT. This 17-year-old girl presented with congenital muscular dystrophy, profound mental retardation, white matter changes and subtle structural abnormalities on brain MRI. Her skeletal muscle biopsy showed reduced immunolabelling of alpha-dystroglycan. Immunoblotting with an antibody to a glycosylated epitope demonstrated a reduced molecular weight form of alpha-dystroglycan that retained some laminin binding activity. This is the first description of mutations in the human LARGE gene and we propose to name this new disorder MDC1D.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12966029     DOI: 10.1093/hmg/ddg307

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  147 in total

1.  Differential glycosylation of α-dystroglycan and proteins other than α-dystroglycan by like-glycosyltransferase.

Authors:  Peng Zhang; Huaiyu Hu
Journal:  Glycobiology       Date:  2011-09-19       Impact factor: 4.313

2.  RPTPζ/phosphacan is abnormally glycosylated in a model of muscle-eye-brain disease lacking functional POMGnT1.

Authors:  C A Dwyer; E Baker; H Hu; R T Matthews
Journal:  Neuroscience       Date:  2012-06-19       Impact factor: 3.590

3.  Absence of post-phosphoryl modification in dystroglycanopathy mouse models and wild-type tissues expressing non-laminin binding form of α-dystroglycan.

Authors:  Atsushi Kuga; Motoi Kanagawa; Atsushi Sudo; Yiumo Michael Chan; Michiko Tajiri; Hiroshi Manya; Yamato Kikkawa; Motoyoshi Nomizu; Kazuhiro Kobayashi; Tamao Endo; Qi L Lu; Yoshinao Wada; Tatsushi Toda
Journal:  J Biol Chem       Date:  2012-01-23       Impact factor: 5.157

4.  Mislocalization of fukutin protein by disease-causing missense mutations can be rescued with treatments directed at folding amelioration.

Authors:  Masaji Tachikawa; Motoi Kanagawa; Chih-Chieh Yu; Kazuhiro Kobayashi; Tatsushi Toda
Journal:  J Biol Chem       Date:  2012-01-24       Impact factor: 5.157

Review 5.  The dystroglycanopathies: the new disorders of O-linked glycosylation.

Authors:  Paul T Martin
Journal:  Semin Pediatr Neurol       Date:  2005-09       Impact factor: 1.636

6.  Targeted disruption of the Walker-Warburg syndrome gene Pomt1 in mouse results in embryonic lethality.

Authors:  Tobias Willer; Belén Prados; Juan Manuel Falcón-Pérez; Ingrid Renner-Müller; Gerhard K H Przemeck; Mark Lommel; Antonio Coloma; M Carmen Valero; Martin Hrabé de Angelis; Widmar Tanner; Eckhard Wolf; Sabine Strahl; Jesús Cruces
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-21       Impact factor: 11.205

7.  Muscle-specific expression of LARGE restores neuromuscular transmission deficits in dystrophic LARGE(myd) mice.

Authors:  Jessica D Gumerson; Carol S Davis; Zhyldyz T Kabaeva; John M Hayes; Susan V Brooks; Daniel E Michele
Journal:  Hum Mol Genet       Date:  2012-12-06       Impact factor: 6.150

8.  Muscular dystrophy associated with alpha-dystroglycan deficiency in Sphynx and Devon Rex cats.

Authors:  Paul T Martin; G Diane Shelton; Peter J Dickinson; Beverly K Sturges; Rui Xu; Richard A LeCouteur; Ling T Guo; Robert A Grahn; Harriet P Lo; Kathryn N North; Richard Malik; Eva Engvall; Leslie A Lyons
Journal:  Neuromuscul Disord       Date:  2008-11-05       Impact factor: 4.296

9.  Mutations in B3GALNT2 cause congenital muscular dystrophy and hypoglycosylation of α-dystroglycan.

Authors:  Elizabeth Stevens; Keren J Carss; Sebahattin Cirak; A Reghan Foley; Silvia Torelli; Tobias Willer; Dimira E Tambunan; Shu Yau; Lina Brodd; Caroline A Sewry; Lucy Feng; Goknur Haliloglu; Diclehan Orhan; William B Dobyns; Gregory M Enns; Melanie Manning; Amanda Krause; Mustafa A Salih; Christopher A Walsh; Matthew Hurles; Kevin P Campbell; M Chiara Manzini; Derek Stemple; Yung-Yao Lin; Francesco Muntoni
Journal:  Am J Hum Genet       Date:  2013-02-28       Impact factor: 11.025

10.  Biochemical and biophysical changes underlie the mechanisms of basement membrane disruptions in a mouse model of dystroglycanopathy.

Authors:  Peng Zhang; Yuan Yang; Joseph Candiello; Trista L Thorn; Noel Gray; Willi M Halfter; Huaiyu Hu
Journal:  Matrix Biol       Date:  2013-02-27       Impact factor: 11.583

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.